Germany · Delayed Price · Currency is EUR Coherus Oncology Statistics
Total Valuation
FRA:8C5 has a market cap or net worth of EUR 141.77 million. The enterprise value is 23.32 million.
| Market Cap | 141.77M |
| Enterprise Value | 23.32M |
Important Dates
The next estimated earnings date is Wednesday, March 4, 2026.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 120.87M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.22% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 6.50% |
| Owned by Institutions (%) | 46.78% |
| Float | 112.99M |
Valuation Ratios
The trailing PE ratio is 1.07.
| PE Ratio | 1.07 |
| Forward PE | n/a |
| PS Ratio | 0.60 |
| PB Ratio | 1.90 |
| P/TBV Ratio | 4.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.18 |
| EV / Sales | 0.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.24 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.26% |
| Return on Invested Capital (ROIC) | -29.64% |
| Return on Capital Employed (ROCE) | -58.14% |
| Revenue Per Employee | 1.50M |
| Profits Per Employee | 835,961 |
| Employee Count | 228 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 4.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.04% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.04% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 48.19 |
| Average Volume (20 Days) | 455 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 23.33 |
Income Statement
In the last 12 months, FRA:8C5 had revenue of EUR 236.71 million and earned 132.08 million in profits. Earnings per share was 1.14.
| Revenue | 236.71M |
| Gross Profit | 133.29M |
| Operating Income | -71.47M |
| Pretax Income | 52.02M |
| Net Income | 132.08M |
| EBITDA | -68.01M |
| EBIT | -71.47M |
| Earnings Per Share (EPS) | 1.14 |
Balance Sheet
The company has 163.35 million in cash and 46.30 million in debt, giving a net cash position of 117.06 million.
| Cash & Cash Equivalents | 163.35M |
| Total Debt | 46.30M |
| Net Cash | 117.06M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 74.81M |
| Book Value Per Share | 0.64 |
| Working Capital | 75.56M |
Cash Flow
| Operating Cash Flow | -76.87M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 56.31%, with operating and profit margins of -30.19% and 55.80%.
| Gross Margin | 56.31% |
| Operating Margin | -30.19% |
| Pretax Margin | 21.98% |
| Profit Margin | 55.80% |
| EBITDA Margin | -28.73% |
| EBIT Margin | -30.19% |
| FCF Margin | n/a |
Dividends & Yields
FRA:8C5 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.22% |
| Shareholder Yield | -2.22% |
| Earnings Yield | 93.17% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:8C5 has an Altman Z-Score of -3.27 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.27 |
| Piotroski F-Score | 4 |